Trial results

A Study of IBI362 9 mg in Chinese Adults With Obesity

NCT06164873 on ClinicalTrials.gov · last registry update 2024-08-27

462 participants. Its estimated completion date, 27 June 2025, has passed with no update to the record. Primary outcome, as filed: Percent Change from Baseline in Body Weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

UNKNOWN

Phase

P3

Drug

mazdutide

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Enrollment

462

Started

2023-12-27

Primary completion

2025-06-27 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.